Aduro BioTech Receives Breakthrough Therapy Designation from FDA for Innovative Pancreatic Cancer Combination Immunotherapy

FDA Breakthrough Designation Highlights Aduro‚Äôs Immunotherapeutic Approach as Promising Treatment for Patients with Pancreatic Cancer July 21, 2014 Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its pancreatic cancer combination treatment that consists of its CRS-207 and GVAX Pancreas immunotherapies. According to the FDA, a …

Vaccine Duo Gives Pancreatic Cancer Patients Two Months Extra

Dr. Le of the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center has announced that a phase II trial has shown that serial administration of two cancer vaccines has produced a positive improvement in the survival times for sufferers of metastatic pancreatic cancer. The trail saw patients receive the GVAX Pancreas vaccine followed by CRS-207. The interim results show that …